PDS Biotechnology reports positive phase 1 study results for PDS0101 immunotherapy for HPV-related c
PDS Biotechnology has completed a successful Phase 1 clinical study of its lead cancer immunotherapy, PDS0101, focused on the treatment of HPV-induced cancers.
These include head and neck, anal, and cervical cancer, as well as anal, vaginal, penile, vulvar and cervical pre-cancerous neoplasias. PDS0101 is based on the company's proprietary Versamune® platform, which is being applied to multiple immuno-oncology products.
Achieved substantial induction of killer T-cells capable of targeting HPV-positive tumors. Well tolerated; no significant toxicities. On track to initiate multiple Phase 2 studies in HPV-related cancers in next 12 months.
Click on this link for more information.
